Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

盘前交易 10-01 08:03:22 EDT

44.65

-1.24

-2.70%

盘前44.86

+0.21+0.47%

07:55 EDT

最高46.25	最低44.60	成交量263.02万
今开46.07	昨收45.89	日振幅3.58%
总市值74.20亿	流通市值72.30亿	总股本1.66亿
成交额1.19亿	换手率1.62%	流通股本1.62亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":44.65,"timestamp":1790798400000,"preClose":45.89,"halted":0,"volume":2630187,"hourTrading":{"tag":"盘前","latestPrice":44.86,"preClose":44.65,"latestTime":"07:55 EDT","volume":1203,"amount":53805.646269,"timestamp":1790855751376,"change":0.21,"changeRate":0.004703,"amplitude":0.026562},"delay":0,"changeRate":-0.027021137502723946,"floatShares":161921007,"shares":166184322,"eps":-3.48,"marketStatus":"盘前交易","change":-1.24,"latestTime":"10-01 08:03:22 EDT","open":46.07,"high":46.245,"low":44.6,"amount":118629455.77035001,"amplitude":0.035847,"askPrice":44.97,"askSize":99,"bidPrice":44.42,"bidSize":99,"shortable":3,"etf":0,"ttmEps":-3.48,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":44.65,"preHourTrading":{"tag":"盘前","latestPrice":44.86,"preClose":44.65,"latestTime":"07:55 EDT","volume":1203,"amount":53805.646269,"timestamp":1790855751376,"change":0.21,"changeRate":0.004703,"amplitude":0.026562},"postHourTrading":{"tag":"盘后","latestPrice":44.5,"preClose":44.65,"latestTime":"19:48 EDT","volume":193643,"amount":8645790.2474,"timestamp":1790812108915,"change":-0.15,"changeRate":-0.003359,"amplitude":0.003359},"volumeRatio":0.5522109984960878,"impliedVol":0.5566,"impliedVolPercentile":0.936},"requestUrl":"/m/hq/s/IONS/tweets","defaultTab":"tweets","newsList":[{"id":"1161973403","title":"异动解读｜Ionis Pharmaceuticals盘中上涨5.15%，连续两项三期试验取得积极结果提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1161973403","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161973403?lang=zh_cn&edition=full","pubTime":"2026-09-29 02:37","pubTimestamp":1790620649,"startTime":"0","endTime":"0","summary":"9月29日，Ionis Pharmaceuticals盘中上涨5.15%，报46.79美元/股，成交额8349.88万美元。两项试验连续成功，叠加此前zilganersen获FDA批准治疗亚历山大病，有效修复了7月心脏病药物eplontersen三期试验失败以来的市场信心。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ionis连获两项三期成功，股价上涨提振信心","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110509386","title":"异动解读｜Ionis Pharmaceuticals盘中下跌5.05%，多项管线利好未能扭转心血管管线失利后持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1110509386","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110509386?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:57","pubTimestamp":1790175464,"startTime":"0","endTime":"0","summary":"9月23日，Ionis Pharmaceuticals盘中下跌5.05%，报43.44美元/股，成交额3311.68万美元。尽管当日公司迎来密集管线利好，股价仍大幅回落。然而，市场对此反应冷淡，盘前涨幅迅速回吐并转为下跌。背景上，公司此前与阿斯利康合作的eplontersen在ATTR心肌病三期试验中未达主要终点，叠加美国银行、TD Cowen等机构接连下调目标价，心血管核心管线的接连失利已严重削弱市场信心，股价自52周高点86.74美元已累计腰斩过半，利好消息短期内难以扭转悲观预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ionis盘中下跌，多项利好难挽抛压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488169","title":"Ionis Pharmaceuticals（IONS）涨超2% 三期试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488169","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669488169?lang=zh_cn&edition=full","pubTime":"2026-09-23 19:15","pubTimestamp":1790162157,"startTime":"0","endTime":"0","summary":"金吾财讯 | Ionis Pharmaceuticals（IONS）美股盘前股价上扬，最新涨2.25%，报46.78美元。消息面上，Ionis Pharmaceuticals的sefaxersen在三期IMAgINATION临床试验达到原发性IgA肾病（IgAN）成人患者主要终点。试验第37周数据显示，sefaxersen可显著降低患者24小时尿蛋白肌酐比值（UPCR），蛋白尿降幅具备统计学与临床意义，该指标是肾损伤核心标志物。这款皮下注射药物的安全性、耐受性与此前研究数据保持一致，未出现新增安全风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/MDYxNTA2ZjhkOWVmNGY4NWFiMzk3MGE5NjBhODhjODE3MzYyMzc3Njg0MzY=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MDYxNTA2ZjhkOWVmNGY4NWFiMzk3MGE5NjBhODhjODE3MzYyMzc3Njg0MzY=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306389","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184074764","title":"异动解读｜Ionis Pharmaceuticals盘前上涨5.9%，多款在研药物三期试验接连达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1184074764","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184074764?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:01","pubTimestamp":1790150471,"startTime":"0","endTime":"0","summary":"9月23日，Ionis Pharmaceuticals盘前上涨5.9%，报47.6美元/股，成交额7.51万美元。消息面上，公司近日迎来多重管线利好共振。其与大冢制药合作的Ulefnersen在治疗FUS基因突变型肌萎缩侧索硬化症的三期Fusion研究中达到主要终点，显著改善患者生存与功能，关键次要终点亦获达成，双方计划与FDA讨论加速审批路径。此外，公司此前已获FDA批准Zilganersen用于治疗亚历山大病，商业化进程持续推进。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ionis多管线告捷，盘前迎来上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116292294","title":"异动解读｜Ionis Pharmaceuticals夜盘上涨5.9%，Ulefnersen三期Fusion研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1116292294","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116292294?lang=zh_cn&edition=full","pubTime":"2026-09-23 14:33","pubTimestamp":1790145188,"startTime":"0","endTime":"0","summary":"9月22日，Ionis Pharmaceuticals夜盘上涨5.9%，报48.45美元/股，成交额25.97万美元。消息面上，公司宣布其试验性药物Ulefnersen在治疗FUS基因突变型肌萎缩侧索硬化症的三期Fusion研究中取得积极顶线结果，主要终点实现具有统计学意义的显著改善。Ulefnersen是一种反义寡核苷酸药物，旨在从根源干预疾病进程，若最终获批将成为FUS-ALS领域首个潜在的疾病修饰疗法，填补该适应症治疗空白。此外，公司另一在研药物Zilganersen的FDA目标审评日期亦定于9月22日，多重催化剂共振推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ionis夜盘大涨，ALS新药三期达主要终点","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172335676","title":"异动解读｜Ionis Pharmaceuticals盘前上涨7.15%，Ulefnersen三期Fusion研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1172335676","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172335676?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:05","pubTimestamp":1790078701,"startTime":"0","endTime":"0","summary":"9月22日，Ionis Pharmaceuticals盘前上涨7.15%，报46.95美元/股，成交额44.1万美元。消息面上，公司宣布其试验性药物Ulefnersen在治疗FUS基因突变型肌萎缩侧索硬化症的三期Fusion研究中取得积极顶线结果，主要终点实现具有统计学意义的显著改善。Ulefnersen是一种反义寡核苷酸药物，旨在从根源干预疾病进程，若最终获批将成为FUS-ALS领域首个潜在的疾病修饰疗法，填补该适应症治疗空白。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ionis盘前上涨，FUS-ALS新药三期达主要终点","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191604640","title":"Ionis Pharmaceuticals：Ulefnersen在Fus-ALS关键终点上取得统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1191604640","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191604640?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078499,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals公司近日宣布，其试验性药物Ulefnersen在治疗FUS基因突变型肌萎缩侧索硬化症的临床研究中，于主要终点上实现了具有统计学意义的显著改善。Ionis Pharmaceuticals凭借其反义寡核苷酸技术平台，致力于开发能够精准靶向疾病根源的创新疗法，Ulefnersen正是这一战略布局下的重要候选药物。公司方面表示，这些令人鼓舞的临床数据将进一步支持Ulefnersen的持续推进，并计划在未来的医学会议上公布详细研究结果，同时与监管机构沟通后续开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115354806","title":"Ionis公布Ulefnersen三期Fusion研究积极顶线结果，推进FUS-ALS首个潜在疾病修饰疗法迈出关键一步","url":"https://stock-news.laohu8.com/highlight/detail?id=1115354806","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115354806?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078494,"startTime":"0","endTime":"0","summary":"Ionis制药公司今日宣布，其针对Ulefnersen的三期Fusion研究取得了积极的顶线结果。这一里程碑式的进展，标志着该公司在推动FUS-ALS首个潜在疾病修饰疗法方面，踏出了至关重要的一步。该研究旨在评估Ulefnersen在治疗特定基因突变型ALS患者中的疗效与安全性。Ulefnersen作为一种反义寡核苷酸药物，其设计初衷是从根源上干预疾病进程。业内观察人士指出，这项突破若最终获得批准，不仅将填补FUS-ALS领域的治疗空白，更可能重塑整个ALS治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124966303","title":"异动解读｜Ionis Pharmaceuticals盘中下跌5.01%，心血管管线接连失利叠加机构下调目标价持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1124966303","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124966303?lang=zh_cn&edition=full","pubTime":"2026-09-19 03:59","pubTimestamp":1789761565,"startTime":"0","endTime":"0","summary":"9月19日，Ionis Pharmaceuticals盘中下跌5.01%，报44.4美元/股，成交额1.46亿美元，股价延续近期跌势。消息面上，公司心血管核心管线近期接连遭遇重挫。两次关键管线的接连失利严重削弱了市场对公司核心研发实力的信心。此外，美国银行将公司目标价从93美元下调至91美元，TD Cowen亦将目标价从108美元下调至94美元，机构预期持续回落加剧了抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ionis心血管管线接连失利，股价承压下行","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124058402","title":"异动解读｜Ionis Pharmaceuticals盘中上涨5.03%，报45.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124058402","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124058402?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:43","pubTimestamp":1789652612,"startTime":"0","endTime":"0","summary":"9月17日，Ionis Pharmaceuticals盘中上涨5.03%，报45.78美元/股，成交额728.41万美元。Ionis Pharmaceuticals所在的生物科技行业中，个股中，Moderna涨5.06%，安进涨0.42%，Hyperliquid Strategies涨7.56%，bioAffinity Technologies涨24.3%，Praxis Precision Medicines涨0.36%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141743387","title":"异动解读｜Ionis Pharmaceuticals盘中下跌5.25%，心血管管线接连失利持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1141743387","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141743387?lang=zh_cn&edition=full","pubTime":"2026-09-17 03:13","pubTimestamp":1789585996,"startTime":"0","endTime":"0","summary":"9月17日，Ionis Pharmaceuticals盘中下跌5.25%，报44.77美元/股，成交额2.02亿美元，股价延续近期跌势。消息面上，公司心血管核心管线接连遭遇重挫。9月8日，公司与诺华联合开发的心脏病药物pelacarsen在晚期临床试验中未达主要终点，当日盘前即暴跌13%。两次关键心血管管线的接连失利严重削弱了市场对公司核心研发实力的信心。此外，美国银行近期将公司目标价从93美元下调至91美元，TD Cowen亦将目标价从108美元下调至94美元，机构预期持续回落加剧了抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ionis心血管管线接连失利，股价持续承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159701623","title":"异动解读｜Ionis Pharmaceuticals盘中下跌6.29%，心脏病药物试验接连失败持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1159701623","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159701623?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:13","pubTimestamp":1789488811,"startTime":"0","endTime":"0","summary":"9月15日，Ionis Pharmaceuticals盘中下跌6.29%，报48.2美元/股，成交额9541.81万美元，股价延续近期颓势。9月8日，公司与诺华联合开发的心脏病药物pelacarsen在晚期临床试验中未达主要终点，当日盘前即暴跌13%。此前7月，公司与阿斯利康合作的Eplontersen针对淀粉样心肌病的三期试验同样宣告失败，股价曾单日暴跌超20%。两次关键心血管管线的接连失利严重削弱了市场对公司核心研发实力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"心脏病药物试验接连失败，Ionis股价承压下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102551583","title":"异动解读｜Ionis Pharmaceuticals盘中下跌7.76%，合作伙伴诺华Lp(a)重磅药III期试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1102551583","media":"行情直击","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102551583?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:39","pubTimestamp":1788874778,"startTime":"0","endTime":"0","summary":"9月8日，Ionis Pharmaceuticals盘中下跌7.76%，报54.08美元/股，成交额9699.92万美元。值得注意的是，这已是Ionis近两个月内遭遇的第二次重大III期试验挫折，此前7月其与阿斯利康合作的eplontersen在ATTR-CM心脏转归试验中同样未达主要终点，当时股价曾单日暴跌逾20%。Ionis Pharmaceuticals是一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，管线横跨神经病学、心脏代谢疾病等领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ionis盘中下跌，诺华合作药III期未达终点","news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176841836","title":"异动解读｜Ionis Pharmaceuticals盘前下跌12.19%，合作伙伴诺华Lp(a)重磅药III期试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1176841836","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176841836?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:44","pubTimestamp":1788864278,"startTime":"0","endTime":"0","summary":"9月8日，Ionis Pharmaceuticals盘前下跌12.19%，报50.95美元/股，成交额499.03万美元。消息面上，公司合作伙伴诺华于9月4日宣布，由Ionis发现并早期开发的pelacarsen在III期LpHORIZON心血管结局试验中未达主要终点。Ionis Pharmaceuticals是一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，管线横跨神经病学、心脏代谢疾病等领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ionis再遭III期失利，盘前重挫超12%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180678017","title":"IONIS制药股价盘前下跌13%，该公司心脏病药物晚期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1180678017","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180678017?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:40","pubTimestamp":1788864030,"startTime":"0","endTime":"0","summary":"IONIS制药股价盘前下跌13%，此前该公司心脏病药物晚期试验失败。","market":"nz","thumbnail":"https://static.tigerbbs.com/58c571cf0b4357240a7b67c1db539b4a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/58c571cf0b4357240a7b67c1db539b4a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"IONIS制药股价盘前下跌13%，该公司心脏病药物晚期试验失败","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142106068","title":"异动解读｜Ionis Pharmaceuticals夜盘下跌9.78%，合作伙伴诺华Lp(a)重磅药III期折戟拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1142106068","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142106068?lang=zh_cn&edition=full","pubTime":"2026-09-08 08:21","pubTimestamp":1788826877,"startTime":"0","endTime":"0","summary":"9月8日，Ionis Pharmaceuticals夜盘下跌9.78%，报52.41美元/股，成交额5.73万美元。消息面上，公司合作伙伴诺华于9月4日宣布，由Ionis发现并早期开发的pelacarsen在III期LpHORIZON心血管结局试验中未达主要终点，尽管该药显著降低了脂蛋白水平，但未能转化为心血管事件风险的降低。Ionis Pharmaceuticals是一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，管线横跨神经病学、心脏代谢疾病等领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"诺华重磅药折戟，Ionis夜盘承压重挫","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141988350","title":"异动解读｜Ionis Pharmaceuticals盘后下跌9.43%，FDA批准亚历山大病新药后股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1141988350","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141988350?lang=zh_cn&edition=full","pubTime":"2026-09-05 04:33","pubTimestamp":1788554017,"startTime":"0","endTime":"0","summary":"9月5日，Ionis Pharmaceuticals盘后下跌9.43%，报55.35美元/股，成交额210.34万美元。消息面上，FDA于9月4日正式批准公司旗下Zanvastro注射液上市，用于治疗儿科及成人亚历山大病患者，较PDUFA目标日期9月22日提前获批。此前公司已将美国以外权益授权给Recordati，获3000万美元首付款及后续里程碑付款。同行业中，安进跌6.37%，Moderna跌0.41%。Ionis Pharmaceuticals是一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，管线横跨神经病学、心脏代谢疾病等领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"FDA批准新药后获利回吐，Ionis盘后走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118939828","title":"FDA批准Zanvastro（Zilganersen）注射液用于儿科及成人亚历山大病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1118939828","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118939828?lang=zh_cn&edition=full","pubTime":"2026-09-04 03:55","pubTimestamp":1788465309,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）正式批准Zanvastro（Zilganersen）注射液上市，用于治疗儿科与成人患者的亚历山大病（Alexander Disease）。这一决定标志着该罕见神经退行性疾病在治疗领域迎来新的突破性选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190367495","title":"异动解读｜Ionis Pharmaceuticals盘中下跌5.06%，报58.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190367495","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190367495?lang=zh_cn&edition=full","pubTime":"2026-09-04 00:51","pubTimestamp":1788454292,"startTime":"0","endTime":"0","summary":"9月3日，Ionis Pharmaceuticals盘中下跌5.06%，报58.23美元/股，成交额9753.25万美元。Ionis Pharmaceuticals所在的生物科技行业中，个股表现分化，其中Ultragenyx Pharmaceutical跌44.35%，Moderna跌4.34%，艾伯维跌0.3%，Hyperliquid Strategies涨7.86%，安进涨0.19%。Ionis Pharmaceuticals是一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，管线横跨神经病学、心脏代谢疾病等领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136465309","title":"异动解读｜Ionis Pharmaceuticals盘中上涨5.39%，报56.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136465309","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136465309?lang=zh_cn&edition=full","pubTime":"2026-07-23 21:57","pubTimestamp":1784815031,"startTime":"0","endTime":"0","summary":"7月23日，Ionis Pharmaceuticals盘中上涨5.39%，报56.92美元/股，成交额2821.87万美元。Ionis Pharmaceuticals所在的生物科技行业中，个股中，艾伯维公司涨0.6%，Argenx SE涨3.77%，再生元制药公司跌1.98%，吉利德科学跌1.98%，安进跌1.22%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionis.com","stockEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.2603},{"period":"3month","weight":-0.4542},{"period":"6month","weight":-0.403},{"period":"1year","weight":-0.3175},{"period":"ytd","weight":-0.4356}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司于1989年在加利福尼亚州注册成立，并于1991年1月将公司注册州变更为特拉华州。该公司花了三十年时间开拓RNA靶向药物，并已发展成为一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，并拥有横跨神经病学、心脏代谢疾病和其他患者高需求领域的强大管道。它继续通过独立和合作开发推进下一代RNA靶向技术，为患有严重疾病的患者提供创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.020204},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.015383},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.032273},{"month":4,"riseRate":0.363636,"avgChangeRate":0.01605},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.042937},{"month":6,"riseRate":0.818182,"avgChangeRate":0.057374},{"month":7,"riseRate":0.727273,"avgChangeRate":0.00605},{"month":8,"riseRate":0.545455,"avgChangeRate":0.026197},{"month":9,"riseRate":0.454545,"avgChangeRate":0.023013},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.002194}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}